TNNI3K Antikörper (Biotin)
-
- Target Alle TNNI3K Antikörper anzeigen
- TNNI3K (TNNI3 Interacting Kinase (TNNI3K))
-
Reaktivität
- Human, Maus, Ratte
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser TNNI3K Antikörper ist konjugiert mit Biotin
-
Applikation
- Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
- Kreuzreaktivität
- Human, Maus, Ratte
- Aufreinigung
- Purified by Protein A.
- Immunogen
- KLH conjugated synthetic peptide derived from human TNNI3K
- Isotyp
- IgG
- Top Product
- Discover our top product TNNI3K Primärantikörper
-
-
- Applikationshinweise
-
WB 1:300-5000
IHC-P 1:200-400 - Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 1 μg/μL
- Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
- Konservierungsmittel
- ProClin
- Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- Store at -20°C for 12 months.
- Haltbarkeit
- 12 months
-
- Target
- TNNI3K (TNNI3 Interacting Kinase (TNNI3K))
- Andere Bezeichnung
- TNNI3K (TNNI3K Produkte)
- Synonyme
- CARK antikoerper, Cark antikoerper, D830019J24Rik antikoerper, TNNI3 interacting kinase antikoerper, serine/threonine-protein kinase TNNI3K antikoerper, TNNI3K antikoerper, LOC100592286 antikoerper, Tnni3k antikoerper
- Hintergrund
-
Synonyms: Cardiac ankyrin repeat kinase, CARK, MGC142099, MGC33828, Serine/threonine protein kinase TNN13K, Serine/threonine-protein kinase TNNI3K, TNI3K_HUMAN, TNNI3 interacting kinase, TNNI3-interacting kinase, Tnni3k.
Background: TNNI3K, also known as CARK, is a 936 amino acid serine/threonine-protein kinase that is highly expressed in heart. Overexpression of TNNI3K leads to improved cardiac function by enhancing beating frequency and increasing contractile force and epinephrine response. TNNI3K suppresses phosphorylation of cardiac troponin I and p38/JNK-mediated apoptosis, therefore protecting the myocardium from ischemic injury. Administration of TNNI3K to mice with myocardial infarction improves cardiac performance and attentuates ventricular remodeling, suggesting that TNNI3K could be a promising target in the treatment of cardiac diseases. There are four isoforms of TNNI3K that are produced as a result of alternative splicing events.
- Gen-ID
- 51086
-